Analyst Stock Ratings: Viking Therapeutics, Inc. (VKTX), CNX Resources Corporation (CNX)

Viking Therapeutics, Inc. (NASDAQ:VKTX) tinted gains of +4.28% (+0.36 points) to US$8.77. The volume of 2.42 Million shares climbed down over an trading activity of 2.85 Million shares. EPS ratio determined by looking at last 12 month figures is -0.45. Over the same time span, the stock marked US$24 as its best level and the lowest price reached was US$3.69. The corporation has a market cap of US$655.73 Million.

Viking Therapeutics, Inc. (NASDAQ:VKTX)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -15.8 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 68 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 1 think it is Hold. Recently, analysts have updated the overall rating to 1.89. 6 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

CNX Resources Corporation (NYSE:CNX) is worth US$2.19 Billion and has recently risen 4.25% to US$11.05. The latest exchange of 3.2 Million shares is below its average trading activity of 3.48 Million shares. The day began at US$10.71 but the price moved to US$10.71 at one point during the trading and finally capitulating to a session high of US$11.06. The stock tapped a 52-week high of US$18.37 while the mean 12-month price target for the shares is US$15.09.

Currently, the stock carries a price to earnings ratio of 3.04, a price to book ratio of 0.51, and a price to sales ratio of 1.26. For the past 5 years, the company’s revenue has grown -11.1%, while the company’s earnings per share has grown 60.3%. With an institutional ownership near 0%, it carries an earnings per share ratio of 3.63.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 3 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 2 analysts call it Underweight, while 2 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.75.